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http://dx.doi.org/10.1016/j.kjms.201Abstract Matrix metalloproteinase (MMP) is involved in the upper airway remodeling process.
We hypothesized that MMP had an additive effect on the formation of recurrent nasal polyp.
We also investigated the association between the functional promoter polymorphism of MMPs
and the intensity of labeling index. Expressions of MMP-2 and MMP-9 were assessed via immu-
nohistochemical staining and compared between different groups, including recurrent nasal
polyps, nonrecurrent nasal polyps, and control nasal mucosa. Two promoter functional
single-nucleotide polymorphisms (rs3918242 for MMP-9 and rs243865 for MMP-2) were selected
to correlate with staining intensity. Expression of MMP-9 was significantly enhanced in gland for
recurrent nasal polyp (p Z 0.016) and nonrecurrent nasal polyp (p Z 0.005) compared to the
control. MMP-2 positivity was significantly increased in surface epithelium for recurrent nasal
polyp (p Z 0.004) compared to the control (p Z 0.061). However, there was no significant
difference in MMP-9 and MMP-2 expressions between recurrent and nonrecurrent nasal polyps.
Genetic polymorphism of MMP-2 and MMP-9 functional promoters was not associated with theof Otolaryngology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, No. 100,
Kaohsiung City, Taiwan.
inet.net (C.-F. Tai).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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MMPs in recurrent nasal polyposis 27intensity of labeling index. These results suggested that up-regulation of MMP-9 in gland and
MMP-2 in surface epithelium was characteristic of both recurrent and nonrecurrent nasal
polyps. Pathogenesis of recurrent nasal polyps may involve a mechanism other than MMP.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Nasal polyposis, a subgroup of chronic rhinosinusitis,
remains one of the most difficult challenges in clinical
rhinology. Its etiology and pathophysiology are still
controversial, medical treatment is unsatisfactory, and
recurrences necessitate repeated surgical interventions.
Histological appearance of nasal polyposis is characterized
by inflammatory cell infiltration, modifications of epithelial
cell differentiation, and tissue remodeling including base-
ment membrane thickening, gland modifications, extra-
cellular matrix (ECM) accumulation, and edema. The fact
that nasal polyposis and asthma share characteristic
inflammatory features and histopathologic findings of
airway remodeling led researchers to investigate the
possibility that the airway remodeling occurring with nasal
polyps was similar to that with asthma.
Matrix metalloproteinases (MMPs), a family of zinc- and
calcium-dependent endopeptidases that can collectively
degrade almost all ECM components, is important in the
process of airway remodeling [1,2]. Among the MMP family,
MMP-2 (72-kD type IV collagenase, gelatinase A) and MMP-9
(92-kD type IV collagenase, gelatinase B) more specifically
hydrolyze denatured collagens (gelatin); native types IV, V,
and XI collagens; and elastin [3e5]. They were character-
istically secreted as latent zymogens that could be acti-
vated in vitro by several proteases, via cleavage of
propeptides [1,2]. Although the substrate specificities of
gelatinases appeared similar, these two enzymes were
known to be synthesized by various cells. MMP-2 was
constitutively produced by numerous cell types, whereas
MMP-9 was produced by inflammatory cells such as macro-
phages [6], neutrophils [7], and airway epithelial cells
[8,9].
Roles of MMPs in lung disease are established. In trans-
genic animal studies, an elevated level of MMP-9 and MMP-
2 was associated with defects in bronchial architecture
[10]. MMPs produced by inflammatory cells appeared to be
responsible for microvascular permeability leading to
edema and cell transmigration, and ECM remodeling in
asthmatic airways [11e13]. MMPs also played a role in
bronchial subepithelial fibrosis in asthmatic airways [13].
Previous studies suggested that polyposis formation
involved ECM protrusion through an initial localized
epithelial defect [14]. Many studies had also mentioned the
occurrence of tissue remodeling and the involvement of
MMPs in the formation of nasal polyp, but the results were
inconsistent and none of them discussed the expression of
MMPs in the recurrent nasal polyp. These findings led us to
investigate the relative expression of MMPs in the nonre-
current and recurrent nasal polyps as compared to control
individuals.Materials and methods
Participants
We recruited 30 fresh patients of bilateral chronic rhinosi-
nusitis with nasal polyposis (CRSwNP) who were admitted to
the Kaohsiung Medical University Hospital for endoscopic
sinus surgery. The diagnosis of CRSwNPwasmadeon thebasis
of the definition in European position paper on rhinosinusitis
and nasal polyps 2007 (EPOS 2007) [15]. Patients with
malignancies or asthma were excluded from the study. After
surgery, we routinely used topical steroid spray for at least 6
months postoperatively. Nasal saline irrigation was also
advised and carried out in the patients. All the patients were
followed weekly for the first month and then monthly for at
least 6 months postoperatively. None had recurrent nasal
polyp 6 months after operation. Recurrence of nasal polyp
was defined as newly developed pedunculated nasal polyps
(instead of cobblestone or polypoid mucosa) fully occupying
the middle meatus in a patient 6 months after surgery, as
seen by either anterior rhinoscope or nasal endoscope.
Recurrence was identified in 32 patients for whom revision
surgerywas performedat our institution. Thirty-one patients
with chronic rhinitis with septal deviation admitted for sep-
tomeatoplasty were recruited as controls. Inferior turbinate
mucosa from control individuals was used for immunohisto-
chemical (IHC) staining. None of the controls reportedmajor
disabling diseases upon enrollment. Information on demo-
graphic characteristics was collected. The study was
approved by the Institutional Review Board (IRB) of our
hospital (KMUH-IRB-940216), and written informed consent
was obtained from each participant.
SNP selection and genotyping
Genomic DNA was extracted from peripheral blood by
a standardmethod. Two promoter functional polymorphisms
were selected from the HapMap project (International Hap-
Map Consortium), bothwith theminor allele frequency10%
in the Han Chinese population. The two promoter functional
single-nucleotide polymorphisms (SNPs) are MMP-9 promoter
functional SNP (rs3918242, i.e., 1562 C/T) and MMP-2
promoter functional SNP (rs243865, i.e., 1306 A/G). Gen-
otyping for the two SNPs was carried out by using the TaqMan
50 nuclease assay (Applied Biosystems, Foster City, CA, USA).
The details were given in our previous studies [16,17].
IHC staining for MMP-2 and MMP-9
IHC analysis was performed on 4-mm-thick paraffin sections.
Paraffin sections of all samples were deparaffinized,
Figure 1. MMP-2 labeling index in epithelium and gland in
each group.
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DAKO Target Retrieval Solution, pH 9.0 (DAKO, Glostrup,
Denmark), to induce antigen retrieval. Endogenous peroxi-
dase in the section was blocked by incubation in 3% hydrogen
peroxide for 5 minutes. After blocking with 0.5% goat serum
for 60 minutes, the sections were incubated with primary
antibodies MMP-2 and MMP-9 (NeoMarkers, Union City, CA,
USA) at room temperature for 1 hour. Then, the DAKO REAL
EnVision Detection kit (DAKO) was applied for 30 minutes.
Finally, sectionswere incubated in30,3-diaminobenzidine for
5 minutes, followed by Mayer’s hematoxylin counterstaining
and mounting. Negative controls were obtained by replacing
the primary antibody with nonimmune serum. Samples of
breast carcinoma known to produce MMP-2 and MMP-9 were
used as positive controls. MMP-2 and MMP-9 expression in
nasal polyp and inferior turbinate mucosa were evaluated
and quantified in surface epithelium and gland. Themethods
to quantify MMP labeling index were identical to those
described by Lechapt-Zalcman et al. [18]. Epithelial labeling
indices were estimated as the percentage of positive surface
epithelial fields over the total number of surface epithelial
fields present on each slide (final magnification 200). For
inferior turbinate mucosa, images of about 20 consecutive
high-power fields were obtained and the positively stained
epithelial fields were counted. For nasal polyps, images of
about 40 consecutive high-power fields were obtained and
the positively stained epithelial fields were counted. Gland
labeling indices were expressed as the percentage of glands
with positive cells over the total number of glands counted in
10 randomly selected high-power fields (final magnification
200). For inferior turbinate mucosa, images of about 80
glands were obtained and the positively stained glands were
counted. For nasal polyps, images of about 40 glands were
obtained and the positively stained glands were counted.
Statistical analysis
ANOVA with post hoc test was used for statistical analysis
(SPSS 16.0 for Windows, SPSS Inc., Chicago, IL, USA). Chi-
square test was used to calculate the relationship
between results of IHC staining and genotyping. A p value of
less than 0.05 was considered to be statistically significant.
Results
Results of IHC staining
In all samples, cytoplasmic immunostaining for MMP-2 and
MMP-9 was observed in the surface epithelium, glands, and
connective tissue. In the surface epithelium, MMP-2 posi-
tivity was present in basal cells and in ciliated cells, where
it was concentrated in the apical part of their cytoplasm,
while MMP-9 immunolabeling was detected mainly in the
basal cells. Intense staining of MMP-9 was also detectable in
polymorphonuclear cells. The differences in the intensity of
IHC staining for each group are detailed in Figs. 1 and 2.
Comparison of IHC labeling index in the recurrent nasal
polyp and control nasal mucosa showed a significant
increase in the surface epithelium for MMP-2 (p Z 0.004),
and a significant increase in the gland for MMP-9
(p Z 0.016). Comparison of IHC labeling index in thenonrecurrent nasal polyp and control nasal mucosa also
showed a significant increase in the gland for MMP-9
(p Z 0.005) and a p value toward significance in the
surface epithelium for MMP-2 (p Z 0.061). However, there
was no significant difference in MMP-2 and MMP-9 labeling
indices between nonrecurrent and recurrent nasal polyps in
either surface epithelium or gland.
Result of genotyping
Results of genotype for these two promoter functional SNPs
and their relation to the intensity of MMP-2 and MMP-9 IHC
Figure 2. MMP-9 labeling index in epithelium and gland in
each group.
Table 1 Relationship between MMP-2 and MMP-9 geno-
type and intensity of labeling index in epithelium and gland
in each group.
Subgroup MMP-9 rs3918242
genotype
MMP-2 rs243865
genotype
CC CT TT GG GA AA
LI in epithelium (%)
r-Polyp 78.75 72.14 92.5 78 74 NA
m-Polyp 67.75 66.25 85 66 30 90
Control 66 62 90 55 29 NA
LI in gland(%)
r-Polyp 61 44 90 65 53 NA
m-Polyp 61.5 65.56 75 65 30 93
Control 40 23.75 10 55 37 NA
LI was expressed as the percentage of epithelium (or glands)
with positive cells over the total number of cells in epithelium
(or glands). All p > 0.05 and do not reach statistical signifi-
cance, which means that the genotype does not correlate with
the LI of MMPs in either epithelium or glands. LI Z labeling
index; m-polyp Z nonrecurrent polyp; NA Z nonapplicable;
r-polyp Z recurrent polyp.
MMPs in recurrent nasal polyposis 29staining are shown in Table 1. The difference in the
intensity of IHC staining for each allele did not reach
statistical significance.
Discussion
To the best of our knowledge, this is the first study to
investigate the expression of MMP-2 and MMP-9 in recurrent
CRSwNP. This study compared the relative protein expres-
sion of MMP-2 and MMP-9 in nonrecurrent nasal polyp,
recurrent nasal polyp, and control mucosa from inferiorturbinate. Distribution of MMP-2 and MMP-9 in nasal polyps
is demonstrated by immunohistochemistry using specific
antibodies. We showed that both control mucosa and nasal
polyp intensely expressed MMP-2 and MMP-9. MMP-9
expression was significantly enhanced in the gland in
recurrent nasal polyps and MMP-2 expression was signifi-
cantly enhanced in the surface epithelium in recurrent
nasal polyps, both compared with control mucosa. As ex-
pected, MMP-9 was expressed mainly in inflammatory cells,
but this was also the case in epithelial cells. We also
observed intense MMP-2 and MMP-9 expression in the glands
and vessels, which was characteristic of nasal polyps.
The relevance of MMP-2 to nasal polyp is controversial.
The presence of MMP-2 in nasal polyp was demonstrated in
several studies [18e21], but only Bhandari et al. [20]
detected a significantly higher MMP-2 mRNA expression in
nasal polyp compared to the control tissue (inferior turbi-
nate). MMP-2 is known to be produced by activated fibro-
blasts, and its role in tissue repair and remodeling within
the respiratory epithelium has been proved in vitro [8].
Surface epithelium injured by inflammation might be
a potential source of MMP-2. This hypothesis is supported by
our IHC results, which showed that injured respiratory
epithelium in recurrent nasal polyp expressed significantly
higher MMP-2 as compared to the control mucosa. There
was also a p value near significance (p Z 0.061) when
comparing MMP-2 labeling index in surface epithelium in
nonrecurrent nasal polyps to that in the control.
The presence of MMP-9 in nasal polyp is also a contro-
versial issue. Clinically, patients with poor-healing reaction
after sinus surgery had more severe edematous and fibrotic
changes [22], and higher amounts of MMP-9 in both nasal
secretions and connective tissue [23] when compared with
good healers. Bhandari et al. [20] stated that they could not
find any MMP-9-positive cells in either nasal polyp or infe-
rior turbinate mucosa. Some previous studies showed that
30 L.-F. Wang et al.MMP-9 was expressed in both surface epithelium and gland,
and its expression was significantly higher in nasal polyp
[24e26]. In our study, MMP-9 was significantly enhanced in
the gland, but not in the surface epithelium, of recurrent
nasal polyps as compared to the control. This supported
a relationship between MMP-9 and ECM remodeling in nasal
polyp. The formation of nasal polyp glands has been well
described histologically, but the cellular mechanisms
remain poorly understood. The “epithelial rupture theory”
postulated that polyp formation results from the protrusion
of connective tissue through an initial epithelial defect,
which is subsequently re-epithelialized [27]. Gland buds
could be formed within this area of re-epithelialization by
epithelial basal cell proliferation and migration into the
underlying connective tissue. As has already been shown for
tracheal gland morphogenesis and ureter bud branching,
some morphological findings suggest the involvement of
MMPs in nasal polyp gland formation [28,29]. Most nasal
polyp glands were either cystically dilated or elongated
tubular glands, suggesting a remodeling and developing
process. Enhanced MMP-9 expression in the gland supports
the hypothesis that MMPs are involved in these morpho-
logical changes.
In this study, we demonstrated that MMPs were highly
expressed in chronic inflammation of the sinuses as
compared to control nasal mucosa. We suggest that this
release pattern of enzymes, released by inflammatory
cells in the pseudocyst formations as well as vascular,
epithelial, and glandular elements, is characteristic of
nasal polyp. However, we found no difference between
nonrecurrent and recurrent nasal polyps. In other words,
we were unable to demonstrate that the MMP-2 and MMP-9
had more up-regulation in the process of recurrent nasal
polyp.
Regulation of MMPs is complex. It is considered that
regulation of MMP activity occurs at three levels: gene
transcription, activation of the secreted proenzyme, and
inhibition by specific and nonspecific inhibitors [30].
Furthermore, MMP-9 protein [24,26,31,32], MMP-9 mRNA
[24,26], MMP-2 protein [19,20], and MMP-2 mRNA [20]
levels were reported to be different in patients with the
CRSwNP. Although Zhang et al. [33] reported that the T
allele of promoter SNP rs3918242 at MMP-9 had a higher
promoter activity, which would lead to a higher produc-
tion of MMP-9, neither a recent study [34] nor our results
found any differential expression between the T and C
alleles. Our results also showed that there was no signifi-
cant difference in MMP-2 labeling index between the A and
G alleles.
Our study had certain limitations. First, because nasal
polyps may recur several years after surgery, extended
follow-up might be required. Second, the sizes of the
samples used for comparing MMP-2 and MMP-9 labeling
index and SNPs were small. We emphasize that this was an
exploratory study and future confirmatory studies may be
warranted. As we did not make any sample size calculation
due to the lack of publications on this subject, the risk of
type II error or an underpowered study is unavoidable.
Third, the use of inferior turbinate mucosa as control might
not be appropriate. However, we were not allowed to
harvest sinus mucosa from patients without sinus lesion by
our hospital IRB due to the ethical issue.In conclusion, this study characterized the MMP-2 and
MMP-9 expression in normal and inflamed upper airways. In
normal nasal tissues, gelatinases in stromal and epithelial
cells could be required for the maintenance of ECM
homeostasis and submucosa gland remodeling. Nasal polyp
exhibited higher levels of MMP-9 in glands and of MMP-2 in
surface epithelium. Based on these results, we suggest that
both MMP-2 and MMP-9 may play a part in the formation of
nasal polyp and, more generally, in inflammatory airway
remodeling. As therapeutic strategies with anti-MMP
molecules are currently being developed [35], local
control of the release and/or activation of MMPs may be
another strategy for the treatment of nasal polyp, which is
a common and disabling disease.Acknowledgments
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